Unlike restrictive diets, GLP-1 therapy addresses the biological drivers of weight gain, making lifestyle changes more effective
This absence of foundational pharmacokinetic information constitutes a major knowledge gap with direct implications for clinical application, dosing strategies, and safety monitoring
While clinical trials have not identified osteoporosis as a documented risk of tirzepatide, the medication's substantial metabolic effects and rapid weight reduction warrant careful consideration of skeletal health
Weight loss as a result of GLP-1s, when medically appropriate, can result in health benefits like lower blood pressure, a lower risk of developing type 2 diabetes, improved sleep and, in some cases, an overall improved quality of life